Abstract 2876
Background
Periampullary adenocarcinomas are a heterogenous group of tumours. Tumour morphology, i.e. intestinal type (I-type) and pancreatobiliary type (PB-type), is a more relevant prognostic factor than anatomical origin. Despite the promising effects of cancer immunotherapy, phase I and II clinical trials have this far been disappointing in pancreas cancer. The aim of this study was to map the spatial distribution of lymphocyte subsets in the tumour microenvironment of periampullary adenocarcinoma, in relation to overall survival (OS) and morphology.
Methods
Multiplexed immunohistochemistry was performed on tissue microarrays with tumours from a well characterized consecutive cohort of 175 patients with resected periampullary adenocarcinoma. A panel of immune cell markers including CD4, CD8a, FoxP3, CD20, CD45RO and pan-cytokeratin was applied.
Results
There was no difference in infiltration levels of different lymphocyte populations when taking into account both stromal and tumour compartments, however, in the latter, there were significantly higher levels of activated CD4+ cells (p = 0.027) in PB-type tumors while activated CD8+ cells (p < 0.001), CD8+ Tregs (p = 0.001) FoxP3+CD45ROhigh cells (p = 0.026) and B-cells (p = 0.011) were significantly higher in I-type tumours. In the stromal compartment, FoxP3+CD45ROhigh cells were significantly higher in I-type tumors (p = 0.004). Several immune signatures were defined, and, notably, signatures with low overall lymphocyte infiltration had a significantly worse OS. Composition of immune signatures and their impact on OS differed depending on the tissue compartment. In the stromal compartment, a signature characterized by high levels of activated CD4+ and CD8+ cells, B-cells, FoxP3+CD45ROhigh cells and low levels of FoxP3+CD45ROlow cells fared significantly better than 6 of 7 defined signatures (p = 0.045, p = 0.006, p = 0.019, p < 0.001 and, p = 0.047, respectively).
Conclusions
These data demonstrate that the composition and clinical impact of immune infiltrates in periampullary adenocarcinoma differ by morphological type as well as localisation. Hence, all these factors should be considered in studies on their prognostic and predictive ability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
Mrs Berta Kamprad Foundation, Skåne University Hospital Research Foundation, Lund University Medical Faculty Research grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract
4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Presenter: Erika Martinelli
Session: Poster Display session 2
Resources:
Abstract
5234 - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).
Presenter: Lotte Bakkerus
Session: Poster Display session 2
Resources:
Abstract
5294 - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers
Presenter: Elizabeth Cartwright
Session: Poster Display session 2
Resources:
Abstract
913 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses
Presenter: Margaret Tempero
Session: Poster Display session 2
Resources:
Abstract
1668 - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.
Presenter: Edouard Auclin
Session: Poster Display session 2
Resources:
Abstract
2559 - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)
Presenter: Hanno Riess
Session: Poster Display session 2
Resources:
Abstract
4897 - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA
Presenter: Xiao-ding Liu
Session: Poster Display session 2
Resources:
Abstract
1755 - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Presenter: Michele Reni
Session: Poster Display session 2
Resources:
Abstract
1902 - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Jae Ho Jeong
Session: Poster Display session 2
Resources:
Abstract